

**TRANSMITTAL
FORM***(to be used for all correspondence after initial filing)*

| | | |
|--|------------------------|-------------------|
| TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i> | Application Number | 09/855,320 |
| | Filing Date | May 14, 2001 |
| | First Named Inventor | Bayer, Robert J. |
| | Art Unit | 1652 |
| | Examiner Name | Rao, Manjunath N. |
| Total Number of Pages in This Submission | Attorney Docket Number | 040853-01-5108-US |

ENCLOSURES (Check all that apply)

| | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request (See Remarks) <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) | <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none">• Return postcard• Exhibits 1, 2, 2A-2D (including a Declaration of Dr. Robert Bayer Under 37 CFR 1.132) |
| Remarks | | The Commissioner is authorized to charge any additional fees to Deposit Account 50-0310. |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | | |
|--------------------|---|-----------------|
| Firm or Individual | Morgan, Lewis & Bockius LLP Todd Esker | Reg. No. 46,690 |
| Signature | | |
| Date | May 16, 2005 | |

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

| | | | |
|-----------------------|------------------------|------|--------------|
| Typed or printed name | Kathryn A. Degliantoni | | |
| Signature | | Date | May 16, 2005 |

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


PATENT
Attorney Docket No.: 040853-01-5108-US
Client Ref. No.: NEO00073

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 16, 2005

MORGAN, LEWIS and BOCKIUS LLP

By: Kathryn Wiegant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert Bayer

Application No.: 09/855,320

Filed: May 14, 2001

For: IN VITRO MODIFICATION OF
GLYCOSYLATION PATTERNS OF
RECOMBINANT GLYCOPEPTIDES

Customer No.: 43850

Confirmation Number: 1113

Examiner: Rao, Manjunath

Technology Center/Art Unit: 1652

RESPONSE TO FINAL OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action dated March 14, 2005, please enter the following amendments and remarks. Since the two-month Response deadline for this Notice (May 14, 2005) was a Saturday, please consider this Monday, May 16, 2005, filing as timely.

Amendments to the Claims are reflected in the listing of claims which begins on page 2

Remarks/Arguments begin on page 23 of this paper.